Tech Company M&A Transactions
Stemcentrx Acquisition
Based in South San Francisco, Stemcentrx was acquired by AbbVie. AbbVie said the transaction price was $10.2 billion.
Transaction Overview
Company Name
Acquired By
Announced On
4/28/2016
Transaction Type
M&A
Amount
$10,200,000,000
M&A Terms
AbbVie will acquire Stemcentrx for approximately $5.8 billion in cash and stock. AbbVie will pay approximately $2.0 billion of the transaction value in cash and fund the remaining portion with stock. In addition, Stemcentrx investors are eligible to receive up to $4 billion in cash for additional, success-based milestone payments for the achievement of certain regulatory and clinical developments.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
450 E Jamie Ct.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Slingerland
Chief Operating Officer
James Strawbridge
Chief Scientific Officer
Scott Dylla
VP - R & D
Robert Garnick
Browse more venture capital transactions:
Prev: 4/28/2016: SnappyData venture capital transaction
Next: 4/28/2016: Erecruit venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs